Article citationsMore>>
Molenaar, J.J., Domingo-Fernandez, R., Ebus, M.E., Lindner, S., Koster, J., Drabek, K., Mestdagh, P., van Sluis, P., Valentijn, L.J., van Nes, J., Broekmans, M., Haneveld, F., Volckmann, R., Bray, I., Heukamp, L., Sprussel, A., Thor, T., Kieckbusch, K., Klein-Hitpass, L., Fischer, M., Vandesompele, J., Schramm, A., van Noesel, M.M., Varesio, L., Speleman, F., Eggert, A., Stallings, R.L., Caron, H.N., Versteeg, R. and Schulte, J.H. (2012) LIN28B Induces Neuroblastoma and Enhances MYCN Levels via Let-7 Suppression. Nature Genetics, 44, 1199-1206.
https://doi.org/10.1038/ng.2436
has been cited by the following article:
-
TITLE:
Inhibition of Neuroblastoma Cell Growth by Difluoromethylornithine (DFMO) and Bortezomib through Suppression of LIN28 and MYCN
AUTHORS:
Maria E. Rich, Ping Zhao, Abhinav B. Nagulapally, Jeffrey Bond, Giselle L. Saulnier Sholler
KEYWORDS:
Neuroblastoma, DFMO, Bortezomib, LIN28B, Glycolytic Metabolism
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.8 No.6,
June
21,
2017
ABSTRACT: Neuroblastoma (NB) is the most common childhood cancer arising from the nervous system. Many high-risk neuroblastoma (HRNB) patients develop relapse after initial response to induction treatment and overall long term survival remains poor (less than 60%), emphasizing the need for new therapeutic approaches and more effective treatments. Combination therapies present a favorable approach to improve efficacy, decrease toxicity, and reduce development of drug resistance. Difluoromethylornithine (DFMO) has shown promise in recent clinical trials as a therapeutic agent in treating HRNB. Proteasomes are known to play an important role in tumor cell growth. Bortezomib was the first proteasome inhibitor shown to have anticancer activity clinically. In this study we explore the mechanistic and therapeutic effects of the novel drug combination of DFMO and bortezomib in NB. Cell proliferation studies demonstrated synergistic inhibition of NB cell growth. Bortezomib induced cleaved caspase-3 apoptotic pathway whereas DFMO induced a cytostatic effect on NB cells. Western blot analyses demonstrated down regulation of MYCN, LIN28 and NF-kB in response to DFMO and bortezomib, pathways that are important in cancer stem cells. A decrease in ATP-per-cell when treated with combination therapy suggests inhibition of glycolytic metabolism in NB cells. DFMO as a single agent or in combination with bortezomib significantly reduced tumor growth in xenograft mice. Given the lack of effective treatments, DFMO coupled with bortezomib offers a potential new therapeutic treatment for children with NB.
Related Articles:
-
Flavio Gimenes Alvarenga, Mahouton Jonas Stephane Houndjo, Adjimon Vincent Monwanou, Jean Bio Chabi Orou
-
Casimir Komenan
-
Erdmann Görg
-
Abdul Alim, Fatema Tuj Johora, Shohel Babu, Abeda Sultana
-
Zheng Yuan